- Home
- KT vs BBIO Comparison
KT vs BBIO Comparison
Compare KT & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KT
- BBIO
- Stock Information
- Founded
- KT 1981
- BBIO 2015
- Country
- KT South Korea
- BBIO United States
- Employees
- KT N/A
- BBIO N/A
- Industry
- KT Telecommunications Equipment
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- KT Telecommunications
- BBIO Health Care
- Exchange
- KT Nasdaq
- BBIO Nasdaq
- Market Cap
- KT 9.8B
- BBIO 9.4B
- IPO Year
- KT 1999
- BBIO 2019
- Fundamental
- Price
- KT $19.74
- BBIO $51.21
- Analyst Decision
- KT
- BBIO Strong Buy
- Analyst Count
- KT 0
- BBIO 16
- Target Price
- KT N/A
- BBIO $64.44
- AVG Volume (30 Days)
- KT 1.5M
- BBIO 2.2M
- Earning Date
- KT 11-07-2025
- BBIO 11-11-2025
- Dividend Yield
- KT 3.25%
- BBIO N/A
- EPS Growth
- KT N/A
- BBIO N/A
- EPS
- KT 2.79
- BBIO N/A
- Revenue
- KT $20,321,486,422.00
- BBIO $235,812,000.00
- Revenue This Year
- KT $6.38
- BBIO $115.49
- Revenue Next Year
- KT N/A
- BBIO $64.61
- P/E Ratio
- KT $13.00
- BBIO N/A
- Revenue Growth
- KT 3.45
- BBIO 7.62
- 52 Week Low
- KT $14.77
- BBIO $21.72
- 52 Week High
- KT $21.61
- BBIO $54.60
- Technical
- Relative Strength Index (RSI)
- KT 41.79
- BBIO 52.92
- Support Level
- KT $19.57
- BBIO $52.20
- Resistance Level
- KT $20.13
- BBIO $54.60
- Average True Range (ATR)
- KT 0.30
- BBIO 2.26
- MACD
- KT -0.05
- BBIO -0.06
- Stochastic Oscillator
- KT 10.51
- BBIO 56.48
About KT KT Corporation
KT is South Korea's largest fixed-line telecom operator, with around 11.5 million fixed-line broadband customers and 9.4 million IPTV customers, and is the second-largest wireless operator with 26 million subscribers. Additionally, it has a number of nontelecom businesses, including real estate, payment processing, artificial intelligence, and IDC/cloud services, many of which are the focus of its growth strategy. The company was formed from the previously government-owned, monopoly telecom business and was listed in 1998. After selling its mobile business in 1994 (forming its mobile competitor, SK Telecom) KT created its own mobile operator in 1997.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.